-

$undefined

N/A

(N/A)

Cytokinetics Inc NASDAQ:CYTK Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

Location: 280 E Grand Ave, California, 94080-4808, US | Website: www.cytokinetics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

5.794B

Cash

1.057B

Avg Qtr Burn

-99.77M

Short % of Float

13.27%

Insider Ownership

0.50%

Institutional Own.

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Aficamten (CK-274) (cardiac myosin inhibitor) Details Heart disease, Hypertrophic cardiomyopathies	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Omecamtiv Mecarbil (cardiac myosin activator) Details Pancreatic cancer, Heart disease, Heart failure	NDA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CK-4021586 (CK-586) (cardiac myosin inhibitor) Details Heart disease, Heart failure	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CK-3828136(CK-136) (cardiac troponin activator) Details Heart failure, Heart disease, Epilepsy	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Reldesemtiv (CK-601) (next-generation fast skeletal muscle troponin activator (FSTA)) Details Amyotrophic lateral sclerosis, Neurodegenerative disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.